Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Cardio-Oncology
When should you consider prescribing dexarazoxane for patients on anthracyclines?
Related Questions
What are your management strategies for malignant pericardial effusion with a high risk of spontaneous hemorrhage, particularly in patients requiring anticoagulation for chronic atrial fibrillation?
What are your top takeaways from ACC 2024?
Would blood pressure measurements taken in the ipsilateral arm where a prior node was removed increase the risk of lymphedema?
In patients with moderate calcific mitral stenosis, possible HFpEF and dyspnea on exertion, how would you differentiate the etiology of the symptoms?
Similar to the HFA-ICOS risk stratification tool for patients on chemotherapy, are there cardiac risk calculators available for use in patients starting immunotherapy?
How do you advise patients on cardiotoxicity when they are expected to receive a low mean heart dose and low cardiac substructure doses with their radiation plan?
Is it worth getting a calcium score on a patient who is already on statin therapy?
When would you consider using Ibutilide for rapid pharmacologic cardioversion of atrial fibrillation?
What are reasonable induction and paralytic agents to use during intubation for patients with acute MI and newly reduced LVEF with biventricular failure?
Following cardiac MRI, what imaging modality would you consider to further evaluate mild aortic regurgitation (regurgitant fraction on cardiac MRI of 26%) and mild to moderate mitral regurgitation secondary to mild bi-leaflet mitral valve prolapse (RF 30%) with low-normal LVEF and incomplete RBBB?
